Amgen (AMGN) | Stock Overview & Key Data
Amgen Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $391.29 on March 2, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Amgen
AMGN
|
187.93B Large-cap | 1.39% | 7.42% | -4.29% | 7.75% | 6.99% | 20.32% | 54.66% | 48.82% | 137.40% | 512.31% | 431.58% |
|
Eli Lilly and
LLY
|
821.31B Mega-cap | -1.72% | 12.38% | 14.18% | 6.32% | 4.53% | 38.28% | 153.07% | 418.42% | 1,433.98% | 2,935.09% | 1,988.48% |
| 555.84B Mega-cap | 1.51% | 3.95% | -3.10% | 10.03% | 13.65% | 53.32% | 46.67% | 48.70% | 108.58% | 263.36% | 290.52% | |
|
Gilead Sciences
GILD
|
165.87B Large-cap | -2.97% | -4.07% | -14.40% | 3.77% | 2.22% | 14.19% | 59.26% | 88.55% | 51.95% | 535.26% | 767.93% |
|
Pfizer
PFE
|
153.59B Large-cap | 1.48% | 2.65% | -2.29% | -1.63% | 3.26% | 6.81% | -34.57% | -32.47% | -19.28% | 36.37% | 17.90% |
| 119.87B Large-cap | 1.21% | -1.33% | -5.81% | 3.59% | 5.20% | 14.83% | -13.65% | -14.05% | -19.16% | 107.59% | 126.89% |
Ownership & Short Interest
Calculate Your Amgen Investment Returns
Long-Term Investment Performance Analysis
Amgen stock price in Jul 2016 was $165.67, A $1,000.00 lump sum investment in Amgen made 9 years ago would be worth approximately $2,115.83 today, representing a strong return of 111.58%. This translates to an annualized return (CAGR) of 7.86%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AMGN's 52-week high and low?
- In the last 52 weeks, Amgen reached a high of $391.29 (on March 2, 2026) and a low of $267.83 (on June 23, 2025).
- What is the market cap and P/E ratio for AMGN?
- Curious about Amgen's size and valuation? Its market capitalization stands at 187.93B. When it comes to valuation, the P/E ratio (trailing twelve months) is 24.22, and the forward P/E (looking ahead) is 14.77.
- Does AMGN pay dividends? If so, what's the yield?
- Yes, Amgen is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.30%, and the company has paid an average of $9.98 per share annually over the past 3 years.
- Who are Amgen's main competitors or similar companies to consider before investing?
When looking at Amgen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY821.31B Healthcare Drug Manufacturers - General 38.28% 153.07% Johnson & Johnson
JNJ555.84B Healthcare Drug Manufacturers - General 53.32% 46.67% Gilead Sciences
GILD165.87B Healthcare Drug Manufacturers - General 14.19% 59.26% Pfizer
PFE153.59B Healthcare Drug Manufacturers - General 6.81% -34.57% Bristol-Myers Squibb
BMY119.87B Healthcare Drug Manufacturers - General 14.83% -13.65% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Amgen Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Amgen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 106.10%, the Debt to Equity ratio from the most recent quarter is 640.28, and its Gross Profit Margin stands at 69.84%.
- What is the recent revenue and earnings growth for AMGN?
- Looking at Amgen's growth, its revenue over the trailing twelve months (TTM) was $37B. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.60%, and quarterly earnings saw a YoY growth of 112.60%.
- How much of AMGN stock is held by insiders and institutions?
- Wondering who owns Amgen stock? Company insiders (like executives and directors) hold about 0.22% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 85.36%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.